Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1981 2
1982 2
1983 4
1984 1
1985 2
1986 1
1987 3
1988 4
1989 7
1990 3
1991 5
1992 7
1993 8
1994 18
1995 9
1996 15
1997 17
1998 14
1999 6
2000 16
2001 21
2002 18
2003 24
2004 24
2005 30
2006 33
2007 38
2008 34
2009 32
2010 29
2011 48
2012 71
2013 75
2014 76
2015 72
2016 73
2017 98
2018 61
2019 38
2020 65
2021 79
2022 63
2023 58
2024 49
2025 50
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,260 results

Results by year

Filters applied: . Clear all
Page 1
Cecum-limited Ischemic Colitis.
Fujihara S, Nishiyama N, Kobara H. Fujihara S, et al. Among authors: nishiyama n. Intern Med. 2025 Mar 15;64(6):979-980. doi: 10.2169/internalmedicine.4078-24. Epub 2024 Jul 4. Intern Med. 2025. PMID: 38960682 Free PMC article. No abstract available.
Perioperative therapies for urological cancers.
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y. Inokuchi J, et al. Among authors: nishiyama n. Jpn J Clin Oncol. 2020 Apr 7;50(4):357-367. doi: 10.1093/jjco/hyaa013. Jpn J Clin Oncol. 2020. PMID: 32115649 Review.
Myeloid Cell Adhesion Molecule 1 (CADM1) Promotes Proinflammatory Signaling in Human Inflammatory Bowel Diseases.
Darlington KC, Shumway AJ, Sona C, Khaled Z, Steinbach EC, Kikuchi Y, Fan S, Gartner V, Clough KM, Nishiyama NC, Ng MK, VanLandingham N, Schaner MR, Silverstein S, Lau G, Lian G, Huan B, Zhu LC, Bantumilli S, Furey B, Chaudhry EA, Kapadia MR, Sadiq TS, Barnes EL, Shanahan MT, Rahbar R, Vilen BJ, Bi X, Chen H, Jain D, Akram M, Wong J, Mangada M, Bain G, Nagy ML, Hav M, Ito A, Yan X, Komatsu M, Awad A, Furey TS, Sethupathy P, Poy MN, Sheikh SZ. Darlington KC, et al. Among authors: nishiyama nc. Cell Mol Gastroenterol Hepatol. 2026;20(1):101618. doi: 10.1016/j.jcmgh.2025.101618. Epub 2025 Aug 27. Cell Mol Gastroenterol Hepatol. 2026. PMID: 40882838 Free PMC article.
Response to Zhong et al.
Nishiyama N, Kobara H. Nishiyama N, et al. Endoscopy. 2024 Jul;56(7):550-551. doi: 10.1055/a-2277-2148. Epub 2024 Jun 27. Endoscopy. 2024. PMID: 38936352 No abstract available.
Reply to Wu et al.
Nishiyama N, Kobara H. Nishiyama N, et al. Endoscopy. 2022 Nov;54(11):1126. doi: 10.1055/a-1904-8093. Epub 2022 Oct 27. Endoscopy. 2022. PMID: 36302363 No abstract available.
Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort.
Saito R, Taoka R, Miki J, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Sazuka T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kinoshita H; Japan Urological Oncology Group. Saito R, et al. Among authors: nishiyama n. Int J Clin Oncol. 2025 Oct;30(10):2106-2117. doi: 10.1007/s10147-025-02833-y. Epub 2025 Jul 21. Int J Clin Oncol. 2025. PMID: 40690100
Bottom-up Synthesis of Nanosheets at Various Interfaces.
Sasaki K, Uchida Y, Nishiyama N. Sasaki K, et al. Among authors: nishiyama n. Chempluschem. 2023 Oct;88(10):e202300255. doi: 10.1002/cplu.202300255. Epub 2023 Aug 7. Chempluschem. 2023. PMID: 37469138 Review.
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
Tomida R, Takahashi M, Matsushita Y, Kojima T, Yamana K, Kandori S, Bando Y, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Matsuda A, Kaneko T, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J; Japanese Urological Oncology Group. Tomida R, et al. Among authors: nishiyama n. Clin Genitourin Cancer. 2024 Jun;22(3):102094. doi: 10.1016/j.clgc.2024.102094. Epub 2024 Apr 15. Clin Genitourin Cancer. 2024. PMID: 38714434
Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study.
Sazuka T, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Sawada A, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Ichikawa T; Japan Urological Oncology Group. Sazuka T, et al. Among authors: nishiyama n. Int J Clin Oncol. 2025 Jul;30(7):1417-1425. doi: 10.1007/s10147-025-02778-2. Epub 2025 May 10. Int J Clin Oncol. 2025. PMID: 40347426
1,260 results